Science News
from research organizations

Combination of ground-breaking treatments offer powerful new path for blood cancer therapies

Date:
March 1, 2017
Source:
Monash University
Summary:
Researchers have identified for the first time how a new class of epigenetic drug engages with the immune system to kill off cancer cells, offering powerful new pathways for enhanced blood cancer therapies.
Share:
FULL STORY

Researchers at Monash University and Peter MacCallum Cancer Centre have identified for the first time how a new class of epigenetic drug engages with the immune system to kill off cancer cells, offering powerful new pathways for enhanced blood cancer therapies.

BET-inhibitors are a relatively new class of drug which work to 'switch off' important cancer-causing genes expressed within tumour cells. International clinical trials of BET-inhibitors for the treatment of blood cancers, such as Acute Myeloid Leukemia, are now underway including at Monash and Peter Mac. However to date, this research has focused on the direct effects of the drugs in inducing cancer cell death and understanding how resistance emerges.

In research published in Cell Reports, the team at Peter Mac and Monash have demonstrated the potential for combining ground-breaking epigenetic and immune-based treatments for more potent results.

Experiments conducted as part of the research, showed that immune-competent mice with lymphoma had a far greater response to BET-inhibitors than their immune-deficient counterparts.

In addition to their primary function, the research showed the BET inhibitors were able to 'switch off' a protein called PD-L1, which is used by tumour cells to hide from the immune system. Through this mechanism, the BET-inhibitors were making tumour cells more sensitive to attack from the immune system.

The power of an activated immune system in eliminating tumour cells has been proven through 'blockbuster' drugs such as 'Keytruda' and 'Opdivo', which also target the PD-L1 pathway. Building on this knowledge, this research confirmed that the combinations of BET-inhibitor with other immune therapies work better in lymphoma than either therapy alone.

Based on laboratory research performed at Peter Mac, the Monash team is currently trialling a combination of a different epigenetic drug called Dinaciclib with the anti-PD1 therapy, Keytruda in relapsed lymphoma, myeloma and chronic lymphocytic leukemia with further clinical trials for the combination therapy likely to emerge as a result of this research.


Story Source:

Materials provided by Monash University. Note: Content may be edited for style and length.


Journal Reference:

  1. Simon J. Hogg, Stephin J. Vervoort, Sumit Deswal, Christopher J. Ott, Jason Li, Leonie A. Cluse, Paul A. Beavis, Phillip K. Darcy, Benjamin P. Martin, Andrew Spencer, Anna K. Traunbauer, Irina Sadovnik, Karin Bauer, Peter Valent, James E. Bradner, Johannes Zuber, Jake Shortt, Ricky W. Johnstone. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Cell Reports, 2017; 18 (9): 2162 DOI: 10.1016/j.celrep.2017.02.011

Cite This Page:

Monash University. "Combination of ground-breaking treatments offer powerful new path for blood cancer therapies." ScienceDaily. ScienceDaily, 1 March 2017. <www.sciencedaily.com/releases/2017/03/170301105532.htm>.
Monash University. (2017, March 1). Combination of ground-breaking treatments offer powerful new path for blood cancer therapies. ScienceDaily. Retrieved May 26, 2017 from www.sciencedaily.com/releases/2017/03/170301105532.htm
Monash University. "Combination of ground-breaking treatments offer powerful new path for blood cancer therapies." ScienceDaily. www.sciencedaily.com/releases/2017/03/170301105532.htm (accessed May 26, 2017).

RELATED STORIES